# Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

> **NCT05617885** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Praful Ravi, MB BCHir, MRCP** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Prostate Cancer
- Non-metastatic Prostate Cancer
- Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Abemaciclib
- **DRUG:** GNRH-A Leuprolide Acetate
- **DRUG:** GNRH-A Goserelin
- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT05617885
- **Lead sponsor:** Praful Ravi, MB BCHir, MRCP
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-09
- **Primary completion:** 2025-07-15
- **Final completion:** 2026-06-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05617885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05617885, "Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05617885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*